JP5506677B2 - 概日リズムの変化を防止するための方法および機器 - Google Patents
概日リズムの変化を防止するための方法および機器 Download PDFInfo
- Publication number
- JP5506677B2 JP5506677B2 JP2010518463A JP2010518463A JP5506677B2 JP 5506677 B2 JP5506677 B2 JP 5506677B2 JP 2010518463 A JP2010518463 A JP 2010518463A JP 2010518463 A JP2010518463 A JP 2010518463A JP 5506677 B2 JP5506677 B2 JP 5506677B2
- Authority
- JP
- Japan
- Prior art keywords
- light
- melatonin
- night
- subject
- filter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000027288 circadian rhythm Effects 0.000 title claims description 41
- 238000000034 method Methods 0.000 title description 24
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 80
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 80
- 229960003987 melatonin Drugs 0.000 claims description 79
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 40
- 230000003287 optical effect Effects 0.000 claims description 28
- 239000003862 glucocorticoid Substances 0.000 claims description 24
- 229960000890 hydrocortisone Drugs 0.000 claims description 20
- 230000007958 sleep Effects 0.000 claims description 15
- 230000002060 circadian Effects 0.000 claims description 7
- 230000033764 rhythmic process Effects 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000014509 gene expression Effects 0.000 description 41
- 230000028327 secretion Effects 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 29
- 230000005540 biological transmission Effects 0.000 description 20
- 230000036626 alertness Effects 0.000 description 18
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 17
- 206010041349 Somnolence Diseases 0.000 description 17
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 17
- 238000005286 illumination Methods 0.000 description 17
- 238000010171 animal model Methods 0.000 description 16
- 230000000903 blocking effect Effects 0.000 description 16
- 101150074181 PER2 gene Proteins 0.000 description 15
- 241000700159 Rattus Species 0.000 description 12
- 208000032140 Sleepiness Diseases 0.000 description 12
- 230000037321 sleepiness Effects 0.000 description 12
- 230000001629 suppression Effects 0.000 description 11
- 101150038243 CLOCK gene Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000003016 hypothalamus Anatomy 0.000 description 10
- 230000004253 retinal exposure Effects 0.000 description 10
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 9
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 201000001098 delayed sleep phase syndrome Diseases 0.000 description 8
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 229940037128 systemic glucocorticoids Drugs 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 210000004100 adrenal gland Anatomy 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000035790 physiological processes and functions Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 208000010340 Sleep Deprivation Diseases 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000008821 health effect Effects 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000004560 pineal gland Anatomy 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 210000003994 retinal ganglion cell Anatomy 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008632 circadian clock Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002650 habitual effect Effects 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 208000018773 low birth weight Diseases 0.000 description 2
- 231100000533 low birth weight Toxicity 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000010363 phase shift Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 102000012431 Acetylserotonin O-Methyltransferase Human genes 0.000 description 1
- 108010022539 Acetylserotonin O-methyltransferase Proteins 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 229910001335 Galvanized steel Inorganic materials 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102100025912 Melanopsin Human genes 0.000 description 1
- 101710202061 N-acetyltransferase Proteins 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 206010041347 Somnambulism Diseases 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000006117 anti-reflective coating Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000009195 dark therapy Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 239000008397 galvanized steel Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 108010005417 melanopsin Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 102000008434 neuropeptide hormone activity proteins Human genes 0.000 description 1
- 108040002669 neuropeptide hormone activity proteins Proteins 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000032633 organ maturation Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008665 sleep physiology Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- -1 tungsten halogen Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0618—Psychological treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
- A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head
- A61N2005/0648—Applicators worn by the patient the applicator adapted to be worn on the head the light being directed to the eyes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Psychology (AREA)
- Social Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Developmental Disabilities (AREA)
- Pathology (AREA)
- Child & Adolescent Psychology (AREA)
- Radiology & Medical Imaging (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/833,072 US7748845B2 (en) | 2002-08-28 | 2007-08-02 | Method and device for preventing alterations in circadian rhythm |
| US11/833,072 | 2007-08-02 | ||
| PCT/CA2007/002196 WO2009015457A1 (en) | 2007-08-02 | 2007-12-05 | Method and device for preventing alterations in circadian rhythm |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535538A JP2010535538A (ja) | 2010-11-25 |
| JP2010535538A5 JP2010535538A5 (enExample) | 2011-01-27 |
| JP5506677B2 true JP5506677B2 (ja) | 2014-05-28 |
Family
ID=39170767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518463A Expired - Fee Related JP5506677B2 (ja) | 2007-08-02 | 2007-12-05 | 概日リズムの変化を防止するための方法および機器 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7748845B2 (enExample) |
| EP (1) | EP2175930B1 (enExample) |
| JP (1) | JP5506677B2 (enExample) |
| KR (1) | KR101511623B1 (enExample) |
| AU (1) | AU2007357066B2 (enExample) |
| CA (1) | CA2695453C (enExample) |
| DK (1) | DK2175930T3 (enExample) |
| ES (1) | ES2419304T3 (enExample) |
| WO (1) | WO2009015457A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1283733A1 (en) | 2000-05-10 | 2003-02-19 | Thomas Jefferson University | Photoreceptor system for melatonin regulation and phototherapy |
| US8841864B2 (en) | 2011-12-05 | 2014-09-23 | Biological Illumination, Llc | Tunable LED lamp for producing biologically-adjusted light |
| US9024536B2 (en) | 2011-12-05 | 2015-05-05 | Biological Illumination, Llc | Tunable LED lamp for producing biologically-adjusted light and associated methods |
| US8686641B2 (en) | 2011-12-05 | 2014-04-01 | Biological Illumination, Llc | Tunable LED lamp for producing biologically-adjusted light |
| US9827439B2 (en) | 2010-07-23 | 2017-11-28 | Biological Illumination, Llc | System for dynamically adjusting circadian rhythm responsive to scheduled events and associated methods |
| US9532423B2 (en) | 2010-07-23 | 2016-12-27 | Lighting Science Group Corporation | System and methods for operating a lighting device |
| US8743023B2 (en) | 2010-07-23 | 2014-06-03 | Biological Illumination, Llc | System for generating non-homogenous biologically-adjusted light and associated methods |
| US9681522B2 (en) | 2012-05-06 | 2017-06-13 | Lighting Science Group Corporation | Adaptive light system and associated methods |
| US9764157B2 (en) | 2011-01-17 | 2017-09-19 | University Of Utah Research Foundation | Methods, systems, and apparatus for reducing the frequency and/or severity of photophobic responses or for modulating circadian cycles |
| EP4245347A3 (en) | 2011-01-17 | 2023-12-06 | University of Utah Research Foundation | Apparatus and methods for reducing frequency or severity of photophobic responses or modulating circadian cycles |
| US10359552B2 (en) | 2011-01-17 | 2019-07-23 | University Of Utah Research Foundation | Methods, systems, and apparatus for reducing the frequency and/or severity of photophobic responses or for modulating circadian cycles |
| ES2400590B1 (es) * | 2011-03-31 | 2013-12-17 | Universidad De Murcia | Dispositivo de iluminación circadiano. |
| US8754832B2 (en) | 2011-05-15 | 2014-06-17 | Lighting Science Group Corporation | Lighting system for accenting regions of a layer and associated methods |
| US9173269B2 (en) | 2011-05-15 | 2015-10-27 | Lighting Science Group Corporation | Lighting system for accentuating regions of a layer and associated methods |
| US8901850B2 (en) | 2012-05-06 | 2014-12-02 | Lighting Science Group Corporation | Adaptive anti-glare light system and associated methods |
| US9778490B2 (en) | 2011-11-04 | 2017-10-03 | Spy Optic Inc. | Therapeutic eyewear |
| US9289574B2 (en) | 2011-12-05 | 2016-03-22 | Biological Illumination, Llc | Three-channel tuned LED lamp for producing biologically-adjusted light |
| US9220202B2 (en) | 2011-12-05 | 2015-12-29 | Biological Illumination, Llc | Lighting system to control the circadian rhythm of agricultural products and associated methods |
| US9913341B2 (en) | 2011-12-05 | 2018-03-06 | Biological Illumination, Llc | LED lamp for producing biologically-adjusted light including a cyan LED |
| US9402294B2 (en) | 2012-05-08 | 2016-07-26 | Lighting Science Group Corporation | Self-calibrating multi-directional security luminaire and associated methods |
| WO2014011581A2 (en) * | 2012-07-10 | 2014-01-16 | Photokinetics, Inc. | Optimization of light filters and illuminants and products derived therefrom |
| EP2901184A4 (en) | 2012-09-26 | 2015-11-18 | 8797625 Canada Inc | MULTILAYER OPTICAL INTERFERENCE FILTER |
| US9174067B2 (en) | 2012-10-15 | 2015-11-03 | Biological Illumination, Llc | System for treating light treatable conditions and associated methods |
| US20140257439A1 (en) * | 2013-03-06 | 2014-09-11 | Verilux, Inc. | Adjustable therapeutic lights |
| US20140268731A1 (en) | 2013-03-15 | 2014-09-18 | Lighting Science Group Corpporation | Low bay lighting system and associated methods |
| AU2014248104B2 (en) | 2013-04-04 | 2018-07-05 | Circadian Zirclight Inc | Lighting systems for protecting circadian neuroendocrine function |
| US9750918B2 (en) * | 2013-04-11 | 2017-09-05 | Circadian Zirclight Inc. | Methods and devices for improving sleep performance in subject exposed to light at night |
| US10722727B2 (en) * | 2013-07-09 | 2020-07-28 | Bonnie Brandes | Therapeutic signal generator |
| US9410664B2 (en) | 2013-08-29 | 2016-08-09 | Soraa, Inc. | Circadian friendly LED light source |
| EP3045941B1 (en) | 2013-09-10 | 2019-11-20 | Mitsui Chemicals, Inc. | Optical material and use therefor |
| EP3045942B1 (en) | 2013-09-10 | 2018-11-07 | Mitsui Chemicals, Inc. | Optical material and use therefor |
| US10234608B2 (en) | 2013-11-15 | 2019-03-19 | University Of Utah Research Foundation | Nanoparticle light filtering method and apparatus |
| US10281627B2 (en) | 2013-11-15 | 2019-05-07 | University Of Utah Research Foundation | Nanoparticle light filtering method and apparatus |
| US20150234207A1 (en) * | 2014-02-17 | 2015-08-20 | Daniel Koifman | Device and method for selective wavelength filtration and selective wavelength transmission for therapeutic effect |
| US10100987B1 (en) | 2014-09-24 | 2018-10-16 | Ario, Inc. | Lamp with directional, independently variable light sources |
| LT6170B (lt) | 2014-10-27 | 2015-06-25 | Uab "Metapro Holding" | Paros širdies ritmo autonominės nervų sistemos balanso analizės sistema |
| US10401683B2 (en) | 2015-01-14 | 2019-09-03 | Soraa, Inc. | Low blue light displays |
| US9943042B2 (en) | 2015-05-18 | 2018-04-17 | Biological Innovation & Optimization Systems, LLC | Grow light embodying power delivery and data communications features |
| USD760398S1 (en) | 2015-06-12 | 2016-06-28 | Verilux, Inc. | Lamp for light therapy |
| USD760913S1 (en) | 2015-06-12 | 2016-07-05 | Verilux, Inc. | Light therapy luminaire |
| US9844116B2 (en) | 2015-09-15 | 2017-12-12 | Biological Innovation & Optimization Systems, LLC | Systems and methods for controlling the spectral content of LED lighting devices |
| US9788387B2 (en) | 2015-09-15 | 2017-10-10 | Biological Innovation & Optimization Systems, LLC | Systems and methods for controlling the spectral content of LED lighting devices |
| CN108431677B (zh) | 2015-12-22 | 2020-02-07 | 依视路国际公司 | 用于刺激非视觉生理效应的方法和眼科元件 |
| WO2017145022A1 (en) | 2016-02-22 | 2017-08-31 | Novartis Ag | Uv/visible-absorbing vinylic monomers and uses thereof |
| WO2017145024A1 (en) | 2016-02-22 | 2017-08-31 | Novartis Ag | Uv-absorbing vinylic monomers and uses thereof |
| US10175508B2 (en) | 2016-03-14 | 2019-01-08 | Younger Mfg. Co. | Photochromic optical lens with selective blue light attenuation |
| US10595376B2 (en) | 2016-09-13 | 2020-03-17 | Biological Innovation & Optimization Systems, LLC | Systems and methods for controlling the spectral content of LED lighting devices |
| KR20180078956A (ko) * | 2016-12-30 | 2018-07-10 | 공주대학교 산학협력단 | 멜라토닌 량 분석에 기초한 수면 유도 조명 장치 및 방법 |
| KR101848290B1 (ko) * | 2017-08-10 | 2018-04-12 | 주식회사 피앤지아이엔씨 | 크라운 전면부 제조방법 및 그를 이용한 모자 |
| EP3737469A4 (en) * | 2018-01-11 | 2021-11-10 | Ecosense Lighting Inc. | CIRCADIAN EFFECT DISPLAY LIGHTING SYSTEMS |
| WO2019140309A1 (en) | 2018-01-11 | 2019-07-18 | Ecosense Lighting Inc. | Switchable systems for white light with high color rendering and biological effects |
| CN110538381B (zh) | 2018-05-29 | 2021-06-22 | 华为技术有限公司 | 光照调整方法及终端 |
| US20200018982A1 (en) * | 2018-07-14 | 2020-01-16 | Beau David Whitaker | Protecting horses and other animals from blue light |
| JP2022514141A (ja) | 2018-09-25 | 2022-02-10 | コーニンクレッカ フィリップス エヌ ヴェ | 概日フェーズ管理のための露光量制御 |
| US12073775B2 (en) | 2018-11-08 | 2024-08-27 | Korrus, Inc. | Display lighting systems with bioactive lighting |
| US20220001200A1 (en) | 2018-11-08 | 2022-01-06 | Ecosense Lighting Inc. | Switchable bioactive lighting |
| US11783748B2 (en) | 2018-11-08 | 2023-10-10 | Korrus, Inc. | Display lighting systems with bioactive lighting |
| KR102135627B1 (ko) * | 2019-01-23 | 2020-07-21 | 국민대학교산학협력단 | 일주기 리듬 관리 장치 및 시스템 |
| JP7228206B2 (ja) | 2019-04-19 | 2023-02-24 | 三井化学株式会社 | 光学材料 |
| CN113692550B (zh) | 2019-04-19 | 2023-11-03 | 三井化学株式会社 | 光学材料、光学材料用聚合性组合物、固化物、塑料透镜、光学材料的应用方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1971941A (en) | 1932-07-22 | 1934-08-28 | Gen Electric | Electric discharge lamp device |
| US3112886A (en) | 1960-02-01 | 1963-12-03 | Leonard H Kushner | Color control |
| US3826751A (en) | 1970-12-07 | 1974-07-30 | American Optical Corp | Selective optical filter and method of manufacture |
| US4500810A (en) | 1980-11-25 | 1985-02-19 | North American Philips Lighting Corporation | Fluorescent lamp having integral light-filtering means and starting aid |
| US4952046A (en) | 1982-02-26 | 1990-08-28 | Stephens James B | Optical lenses with selective transmissivity functions |
| US4719248A (en) | 1985-08-08 | 1988-01-12 | Bausch & Lomb Incorporated | Ultraviolet blocking agents for contact lenses |
| US5177509A (en) | 1987-02-26 | 1993-01-05 | Suntiger, Inc. | Ultraviolet radiation and blue light blocking polarizing lens |
| US4878748A (en) | 1987-02-26 | 1989-11-07 | Suntiger, Inc. | Ultraviolet radiation and blue light blocking polarizing lens |
| US5167228A (en) | 1987-06-26 | 1992-12-01 | Brigham And Women's Hospital | Assessment and modification of endogenous circadian phase and amplitude |
| US5274403A (en) | 1987-08-28 | 1993-12-28 | Gott George M | Lens useful in inhibiting the production of melatonin and lens produced thereby |
| US5083858A (en) | 1989-04-17 | 1992-01-28 | Girerd Rene J | Photobiologic sunglasses and transmitters |
| US6638963B1 (en) | 1990-12-04 | 2003-10-28 | Oregon Health And Science University | Methods for treating circadian rhythm disorders |
| US6019476A (en) | 1996-06-24 | 2000-02-01 | Kirschner; Kevin A. | Full spectrum filtering for fluorescent lighting |
| JP3357803B2 (ja) | 1996-10-30 | 2002-12-16 | タレックス光学工業株式会社 | 眼鏡用偏光膜および偏光眼鏡 |
| DE19729719A1 (de) | 1997-07-11 | 1998-02-12 | Bock Manfred | Lampenkörper mit Farbmischvorrichtung |
| US6235046B1 (en) * | 1998-01-21 | 2001-05-22 | David W. Gerdt | Passive photonic eye delivery system |
| US6156743A (en) | 1999-10-18 | 2000-12-05 | Whitcomb; John E. | Method of decreasing fatigue |
| GB2378656A (en) | 2001-08-14 | 2003-02-19 | Stephen Bryce Hayes | Means for modulation of circadian rhythms |
| US6902296B2 (en) | 2002-06-15 | 2005-06-07 | Searfoss, Iii Robert Lee | Nightlight for phototherapy |
| AU2003264202A1 (en) | 2002-08-28 | 2004-03-19 | Robert Casper | A device for the prevention of melatonin suppression by light at night |
| EP1619648A4 (en) * | 2003-03-28 | 2008-08-06 | Sharp Kk | DISPLAY DEVICE |
| US10252079B2 (en) | 2003-06-06 | 2019-04-09 | Koninklijke Philips N.V. | Hand-held light therapy apparatus |
| US6926405B2 (en) | 2003-06-06 | 2005-08-09 | Younger Mfg. Co. | Eyewear lens having selective spectral response |
| CA2532657A1 (en) | 2003-07-14 | 2005-01-20 | Charles A. Czeisler | Method for modifying or resetting the circadian cycle using short wavelength light |
| CA2552122A1 (en) * | 2003-12-29 | 2005-07-21 | Advanced Medical Optics, Inc. | Intraocular lenses having a visible light-selective-transmissive-region |
| JP4544948B2 (ja) * | 2004-03-26 | 2010-09-15 | シャープ株式会社 | 画像表示制御装置 |
| JP4743835B2 (ja) * | 2004-12-27 | 2011-08-10 | Ｈｏｙａ株式会社 | 光学レンズのコーティング装置 |
-
2007
- 2007-08-02 US US11/833,072 patent/US7748845B2/en not_active Expired - Lifetime
- 2007-12-05 WO PCT/CA2007/002196 patent/WO2009015457A1/en not_active Ceased
- 2007-12-05 KR KR1020107004719A patent/KR101511623B1/ko not_active Expired - Fee Related
- 2007-12-05 DK DK07855478.9T patent/DK2175930T3/da active
- 2007-12-05 JP JP2010518463A patent/JP5506677B2/ja not_active Expired - Fee Related
- 2007-12-05 AU AU2007357066A patent/AU2007357066B2/en not_active Ceased
- 2007-12-05 CA CA2695453A patent/CA2695453C/en not_active Expired - Fee Related
- 2007-12-05 EP EP07855478A patent/EP2175930B1/en not_active Not-in-force
- 2007-12-05 ES ES07855478T patent/ES2419304T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2175930T3 (da) | 2013-06-24 |
| US20080065177A1 (en) | 2008-03-13 |
| JP2010535538A (ja) | 2010-11-25 |
| EP2175930B1 (en) | 2013-03-27 |
| EP2175930A4 (en) | 2011-06-29 |
| AU2007357066B2 (en) | 2014-08-21 |
| CA2695453C (en) | 2016-11-29 |
| ES2419304T3 (es) | 2013-08-20 |
| WO2009015457A1 (en) | 2009-02-05 |
| KR20110000618A (ko) | 2011-01-04 |
| CA2695453A1 (en) | 2009-02-05 |
| KR101511623B1 (ko) | 2015-04-14 |
| US7748845B2 (en) | 2010-07-06 |
| AU2007357066A1 (en) | 2009-02-05 |
| EP2175930A1 (en) | 2010-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5506677B2 (ja) | 概日リズムの変化を防止するための方法および機器 | |
| Wahl et al. | The inner clock—Blue light sets the human rhythm | |
| Wong et al. | A review of the current state of research on artificial blue light safety as it applies to digital devices | |
| Tähkämö et al. | Systematic review of light exposure impact on human circadian rhythm | |
| Rüger et al. | Human phase response curve to a single 6.5 h pulse of short‐wavelength light | |
| Arns et al. | Identification and management of circadian rhythm sleep disorders as a transdiagnostic feature in child and adolescent psychiatry | |
| Bijlenga et al. | The role of the circadian system in the etiology and pathophysiology of ADHD: time to redefine ADHD? | |
| Najjar et al. | Temporal integration of light flashes by the human circadian system | |
| Wright et al. | Differential effects of light wavelength in phase advancing the melatonin rhythm | |
| Abbott et al. | The ipRGC-driven pupil response with light exposure, refractive error, and sleep | |
| Aries et al. | Daylight and health: A review of the evidence and consequences for the built environment | |
| Anderson et al. | Lux vs. wavelength in light treatment of Seasonal Affective Disorder | |
| Roecklein et al. | Melanopsin, photosensitive ganglion cells, and seasonal affective disorder | |
| US20150192800A1 (en) | Optimization of light filters and illuminants and products derived therefrom | |
| Wright et al. | Light emitting diodes can be used to phase delay the melatonin rhythm | |
| Rosenthal et al. | A multicenter study of the light visor for seasonal affective disorder: no difference in efficacy found between two different intensities | |
| Münch et al. | Melanopsin-mediated acute light responses measured in winter and in summer: seasonal variations in adults with and without cataracts | |
| Schmidt et al. | Light exposure via a head‐mounted device suppresses melatonin and improves vigilant attention without affecting cortisol and comfort | |
| Figueiro | Individually tailored light intervention through closed eyelids to promote circadian alignment and sleep health | |
| Atan et al. | The effect of blindness on biological rhythms and the consequences of circadian rhythm disorder | |
| Kosanovic Rajacic et al. | Illuminating the way: the role of bright light therapy in the treatment of depression | |
| Park et al. | Effects of evening exposure to light from organic light-emitting diodes on melatonin and sleep | |
| Chan et al. | Attenuated melanopsin-mediated post-illumination pupillary response is associated with reduced actigraphic amplitude and mesor in older adults | |
| Østergaard Madsen et al. | Seasonal variation in neurohormones, mood and sleep in patients with primary open angle glaucoma–implications of the ipRGC-system | |
| Kubota et al. | Effects of different light incident angles via a head-mounted device on the magnitude of nocturnal melatonin suppression in healthy young subjects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101206 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111206 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120912 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120920 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121211 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130312 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130627 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20131011 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131025 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131011 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131204 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20131227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140217 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140318 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5506677 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |